



December 1, 2015

## Ophthotech Corporation to Host R&D Investor Day on December 3, 2015

**- Webcast to Begin at 8:30 a.m. Eastern Time -**

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that the Company will host a live webcast in conjunction with its Research and Development (R&D) Investor Day on Thursday, December 3, 2015, beginning at 8:30 a.m. ET. Ophthotech's management will provide an overview of the Company's Fovista<sup>®</sup> (pegpleranib) programs in the current treatment paradigm of wet age-related macular degeneration. The Company will host a panel discussion with a leading group of retina specialists.

The live and archived webcast can be accessed through the Investor section of the Company's website at [www.opthotech.com](http://www.opthotech.com). Please connect to Ophthotech's website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay will remain available on the Company's website for 14 days following the presentation.

### About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista<sup>®</sup> anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura<sup>®</sup>, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD. For more information, please visit [www.opthotech.com](http://www.opthotech.com).

### Forward-looking Statements

*Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.*

### OPHT-G

View source version on [businesswire.com](http://businesswire.com): <http://www.businesswire.com/news/home/20151201005170/en/>

### Investors

Kathy Galante  
Ophthotech Corporation  
Vice President, Investor Relations and Corporate Communications  
212-845-8231  
[kathy.galante@opthotech.com](mailto:kathy.galante@opthotech.com)

or

### Media

Jennifer Devine  
SmithSolve LLC on behalf of Ophthotech Corporation  
973-442-1555 ext. 102  
[jennifer.devine@smithsolve.com](mailto:jennifer.devine@smithsolve.com)

Source: Ophthotech Corporation

News Provided by Acquire Media